Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Métodos Terapéuticos y Terapias MTCI
Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Intern Med ; 62(8): 1157-1166, 2023 Apr 15.
Artículo en Inglés | MEDLINE | ID: mdl-36070948

RESUMEN

A 59-year-old woman presented to our hospital with liver dysfunction. Imaging revealed multiple lesions in the liver. The patient was diagnosed with peliosis hepatis using percutaneous and laparoscopic biopsies. However, her condition worsened with the appearance of new, obvious mass-forming lesions. Therefore, she underwent a second percutaneous biopsy of these lesions and was diagnosed with hepatic angiosarcoma. Her condition progressed rapidly, and she died two weeks after the diagnosis. Diagnosis of hepatic angiosarcoma in the early stages is difficult. It should be noted that hepatic angiosarcoma may be associated with the development of peliosis hepatis.


Asunto(s)
Hemangiosarcoma , Neoplasias Hepáticas , Peliosis Hepática , Femenino , Humanos , Persona de Mediana Edad , Peliosis Hepática/diagnóstico , Peliosis Hepática/diagnóstico por imagen , Hemangiosarcoma/diagnóstico por imagen , Hígado/patología , Neoplasias Hepáticas/diagnóstico , Neoplasias Hepáticas/diagnóstico por imagen
2.
Oncology ; 98(5): 295-302, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32097925

RESUMEN

BACKGROUND/AIM: Few studies have examined the details of nutritional status in patients with unresectable hepatocellular carcinoma (u-HCC) undergoing systemic chemotherapy with lenvatinib. We evaluated the prognostic/predictive value of nutritional status using Onodera's prognostic nutritional index (O-PNI) for overall survival among patients with u-HCC treated with lenvatinib. METHODS: Three-hundred and seventy-five u-HCC patients treated with lenvatinib were enrolled (median age 72 years; Child-Pugh class A/B/C: n = 312/60/3; BCLC stage A/B/C/D: n = 2/159/212/2). We examined median survival time (MST) and time to progression (TTP) in all patients (n = 375), prognosis according to the O-PNI (high/low: >40/≤40) in 298 patients with lymphocyte findings, and the prognostic/predictive values of Child-Pugh stage, albumin-bilirubin (ALBI)/modified ALBI (mALBI) grade, and O-PNI for Chemotherapy grade (OPNIC grade 1/2/3: O-PNI >40/≤40 to >36/≤36). RESULTS: The MST and TTP were 16.6 and 8.0 months, respectively. The MST and TTP according to the O-PNI (>40/≤40) were "not reached" (NR)/12.4 months (p < 0.001) and 10.0/6.1 months (p = 0.012), respectively. There was a good correlation noted between ALBI score and O-PNI (r = -0.939, p < 0.001). The predictive value of the O-PNI for mALBI grade 2a was 36.0 (specificity/sensitivity = 0.894/0.942; area under the curve [AUC] = 0.978), while that for mALBI grade 1 was 39 (specificity/sensitivity = 0.920/0.929; AUC = 0.972), which was very similar to a high O-PNI. The MST analyzed with the OPNIC in the 298 patients was NR/16.2/10.4 months for OPNIC grade 1/2/3 (p < 0.001), respectively, and the c-index was 0.632, the same as that for mALBI grade (0.632), while that for Child-Pugh class was 0.571. CONCLUSIONS: OPNIC grading might have a potential for easy substitution of mALBI grading. A good nutritional status (OPNIC grade 1) or mALBI grade 1 is the best indication for lenvatinib use, while with an OPNIC grade 3, lenvatinib might be not suitable.


Asunto(s)
Carcinoma Hepatocelular/tratamiento farmacológico , Carcinoma Hepatocelular/patología , Neoplasias Hepáticas/tratamiento farmacológico , Neoplasias Hepáticas/patología , Compuestos de Fenilurea/uso terapéutico , Quinolinas/uso terapéutico , Anciano , Bilirrubina/metabolismo , Biomarcadores de Tumor/metabolismo , Carcinoma Hepatocelular/metabolismo , Femenino , Humanos , Estimación de Kaplan-Meier , Pruebas de Función Hepática/métodos , Neoplasias Hepáticas/metabolismo , Masculino , Evaluación Nutricional , Pronóstico , Albúmina Sérica Humana/metabolismo
3.
Intern Med ; 42(12): 1188-92, 2003 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-14714956

RESUMEN

Dietary supplements have become very popular worldwide because they are believed to be safe with few side effects. Here, we report three cases of liver injury caused by Sennomotokounou, a Chinese dietary supplement for weight reduction. All patients developed acute hepatotoxicity and recovered spontaneously after withdrawal of dietary product. This product contains fenfluramine, n-nitroso-fenfluramine, and dried thyroid tissue powder. In Japan, the regulatory agency for drug and food safety received 120 reports of hepatotoxicity associated with Sennomotokounou between 2000 and 2002. Physicians should inquire about the use of dietary supplements whenever patients present with unexplained acute liver dysfunction.


Asunto(s)
Fármacos Antiobesidad/efectos adversos , Medicamentos Herbarios Chinos/efectos adversos , Fenfluramina/efectos adversos , Fallo Hepático Agudo/inducido químicamente , Adulto , Femenino , Humanos , Hipertiroidismo/inducido químicamente , Fallo Hepático Agudo/patología , Persona de Mediana Edad
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA